The global chemotherapy-induced neutropenia treatment market is projected to reach approximately USD 0.6 billion by 2033, up from USD 0.5 billion in 2023, reflecting a compound annual growth rate (CAGR) of 3.4% over the forecast period from 2023 to 2033.